Dear Editor,

Sildenafil citrate (Viagra®; Pfizer Pharmaceuticals, New York, NY, USA), a selective inhibitor of phosphodiesterase type 5 (PDE-5), is widely used for erectile dysfunction. Its clinical recommended dosage is 25 to 100 mg per day. The most common ocular side-effects are blurred vision and impaired blue/green colour discrimination[1-3]. Mild and transient visual disturbances are often ignored by patients taking the recommended dose or resolve before the patient sees a doctor. Moreover, little attention has been paid to side-effects in patients who have overdosed sildenafil citrate. Herein, we report a case in a female patient with binocular visual disturbance, possibly due to outer retina damage in the foveal area, following consumption of a high dose (2000 mg) of sildenafil citrate. The case study was approved by the Ethics Committee of Beijing Tongren Hospital. Written informed consent was obtained from the patient.

A 32-year-old woman was referred to our outpatient clinic with a chief complaint of blurry vision in both eyes for 1d. Her history was insignificant except for having taken 2000 mg of sildenafil. One day before, she had taken 2000 mg of sildenafil impulsively after quarrelling with her husband. Sixty minutes later, symptoms began to manifest, including flushing, dizziness, colour vision defects, and blurred vision. One day later, her symptoms had resolved with the exception of blurred vision. Comprehensive ocular examinations were performed in our hospital. Best-corrected visual acuity (BCVA) was 0.7 in the right eye and 0.8 in the left eye. Intraocular pressure and anterior segment were normal in both eyes. There was no obvious abnormality in the fundus, but mild pigment alteration was present in the fovea (Figure 1A, 1B). Fundus autofluorescence did not show abnormal signs in either eye (Figure 1C, 1D). Optical coherent tomography (OCT) revealed abnormal hyporeflectivity of the ellipsoid zone, the outer segments of photoreceptors and the interdigitation zone in the binocular foveal area (Figure 1E, 1F).

Seventeen days after the drug was taken, BCVA was 0.8 in right eye and 0.9 in left eye. Fluorescence fundus angiography (FFA) did not reveal abnormal signs in either eye (Figure 2A, 2B). The abnormal hyporeflectivity of the ellipsoid zone in the binocular foveal area had evidently improved, however, damage to the outer segments of photoreceptors and the interdigitation zone was still present (Figure 2C, 2D). Thirty-eight days after the drug was taken, in a telephone interview, we were informed that her visual acuity was recovered completely without any intervention. However, she refused to come back for further follow-up and examination.

Sildenafil was originally intended for treatment of erectile dysfunction. The pharmacological mechanism of action blocks the degradation pathway of cGMP by inhibiting PDE-5 selectively, and as a result, increased levels of cGMP induce relaxation of the smooth muscle of the corpus cavernosum, causing an inflow of blood to facilitate an erection. Notably, it also has approximately 10% effectiveness on the inhibition of PDE-6[4]. PDE-6, a critical enzyme of the photoreceptor transduction cascade, regulates the Na+ channels in the outer segment of photoreceptors[5]. Thus, concerns about its potential toxic effect on the retina have been widely raised[1-2,4-9]. In this case, our observations are consistent with PDE inhibitor-associated retinal toxicity, characterized by damage to the photoreceptor[5,10].

Previous studies have evaluated the impact of sildenafil on human visual function after a single[6-7,10] or chronic[8] large doses using electrophysiological techniques. However, the results have been contradictory. As previously reported, the incidence of vision disturbance is dose-dependent: approximately 3% of men taking 25 mg, up to 11% taking 100 mg, 50% taking 200 mg, and 100% of men taking 600 and 800 mg of sildenafil experienced visual disturbances[3]. Preclinical animal studies conducted by Pfizer, Inc. also showed that sildenafil did not have a significant effect on electoretinogram
(ERG) parameters until the dosage reached nearly 10 times that of the recommended dose. In this patient, the dosage of sildenafil was much higher than the recommended dose, and the visual disturbances may be attributed to two effects. Firstly, partial inhibition of PDE-6, an important enzyme that is involved in the activation and modulation of the phototransduction cascade, could result in the colour vision defects and blurred vision. Secondly, PDE-5 inhibition increases nitric oxide levels and potentiates the vasodilation effect, consequently, acute changes in ocular perfusion pressure could result in retinal damage. The peak plasma concentration of sildenafil occurs at approximately 30-60min, and elimination half-time is approximately 3-5h when administered within the therapeutic dosage. The early disappearance of general symptoms and colour vision disturbances may be closely related to the drug metabolism, and the delayed improvement of visual acuity may be attributed to the chronic recovery of the photoreceptors’ structure. The later telephone interview seems to confirm that the ocular side-effects can be reversible. Longer-term follow-up, however, is required to make any statement regarding whether the changes noted were reversible or not. Moreover, as shown by OCT, choroidal thickness
Ocular side-effects of overdosed sildenafil

appears to be thicker than usual. Given that choroidal thickness can be affected by multiple factors and was not measured at baseline, a vasodilatory effect of sildenafil on the choroidal circulation\textsuperscript{[13-14]} is uncertain in this case.

In summary, we firstly reported a female case of binocular visual disturbance possibly due to outer retina damage in the foveal area following consumption of an overdose of sildenafil. Patients should be warned about the visual side-effects in cases of misuse.

ACKNOWLEDGEMENTS

Conflicts of Interest: Li YY, None; Yu YJ, None; Liu XP, None; Liu NP, None.

REFERENCES